New roles explored for nucleoside reverse transcriptase inhibitors New research suggests nucleoside reverse transcriptase inhibitors (NRTIs) have intrinsic anti-inflammatory activity through suppression of NLRP3 inflammasome.…
Lipophilic bisphosphonates used to target lung cancer A new generation of lipophilic bisphosphonates has been designed to target cancer, with a zoledronic acid analogue demonstrating efficacy against lung adenocarcinoma.…
Pipeline November 2014 The latest approvals and positive opinions from the European Medicines Agency.…
Role for memantine in treating binge-eating disorder Research findings support a role for memantine as a potential pharmacological treatment for binge-eating disorder.…
Immune checkpoint inhibitors bring new hope to cancer patients PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
Breakthrough in targeting KRAS gene mutation implicated in many cancers Researchers have identified an agent that interferes with the cell signalling protein KRAS and which produces a dose-dependent reduction in tumour growth in a mouse model.…
UK bill aims to allow off-patent drugs to be licensed for new purposes A bill going through Parliament wants the National Institute for Health and Care Excellence (NICE) to appraise off-patent drugs to allow them to be used for new indications.…
Biomarker test could help reduce unnecessary antibiotic prescribingPoint-of-care testing for a biomarker of bacterial infection would help to limit unnecessary antibiotic prescribing by GPs, suggests a systematic review.…
Experimental drug holds promise for Ewing sarcoma patients Strategy for interfering with DNA repair offers potential treatment for Ewing sarcoma.…